Xeris Biopharma Holdings Shares Soared 26% on Recorlev FDA Approval
<p><a href='https://financialmodelingprep.com/financial-summary/XERS'>Xeris Biopharma Holdings, Inc. (Nasdaq:XERS) </a>shares soared more than 26% yesterday driven by the company’s announcement regarding the U.S. Food and Drug Administration (FDA) approval of its Recorlev® (levoketoconazole). </p><p>According to the announcement, Recorlev®, which is used for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s Syndrome, was approved by FDA, making it a safe and effective therapeutic option for patients for whom surgery is not an option or has not been curative.</p>
Nasdaq:, XERS